Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1965 1
1978 1
1980 1
1982 2
1983 1
1984 7
1985 2
1986 12
1987 10
1988 4
1989 14
1990 7
1991 7
1992 11
1993 13
1994 14
1995 24
1996 14
1997 20
1998 16
1999 15
2000 15
2001 20
2002 22
2003 19
2004 23
2005 18
2006 22
2007 16
2008 19
2009 28
2010 28
2011 30
2012 32
2013 35
2014 37
2015 45
2016 50
2017 69
2018 64
2019 61
2020 72
2021 85
2022 86
2023 96
2024 48

Text availability

Article attribute

Article type

Publication date

PubMed for id: 78652

1,141 results

Results by year

Filters applied: . Clear all
Page 1
Cost-effectiveness of ambroxol in the treatment of Gaucher disease type 2.
Milosavljević MN, Gutić M, Janjić V, Veselinović S, Djordjić M, Ivanović R, Milosavljević J, Janković SM. Milosavljević MN, et al. Open Med (Wars). 2024 May 21;19(1):20240970. doi: 10.1515/med-2024-0970. eCollection 2024. Open Med (Wars). 2024. PMID: 38799251 Free PMC article.
Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors.
Lin FY, Stuckert A, Tat C, White M, Ruggieri L, Zhang H, Mehta B, Lapteva N, Mei Z, Major A, Thakkar S, Shum T, Parikh K, Wu MF, Lindsay HB, Scherer L, Shekar M, Baxter P, Wang T, Grilley B, Moeller K, Hicks J, Roy A, Anastas J, Malbari F, Aldave G, Chintagumpala M, Blaney S, Parsons DW, Brenner MK, Heslop HE, Rooney CM, Omer B. Lin FY, et al. J Clin Oncol. 2024 May 21:JCO2302019. doi: 10.1200/JCO.23.02019. Online ahead of print. J Clin Oncol. 2024. PMID: 38771986
Administration of intratumoral GD2-directed interleukin-2 immunocytokine and local radiation therapy to activate immune rejection of spontaneous canine melanoma.
Albertini MR, Zuleger CL, Ranheim EA, Shiyanbola O, Sondel PM, Morris ZS, Eickhoff J, Newton MA, Ong IM, Schwartz RW, Hayim R, Kurzman ID, Turek M, Vail DM. Albertini MR, et al. Melanoma Res. 2024 May 20. doi: 10.1097/CMR.0000000000000975. Online ahead of print. Melanoma Res. 2024. PMID: 38768442
Safety and biological outcomes following a phase 1 trial of GD2-specific CAR-T cells in patients with GD2-positive metastatic melanoma and other solid cancers.
Gargett T, Truong NTH, Gardam B, Yu W, Ebert LM, Johnson A, Yeo ECF, Wittwer NL, Tapia Rico G, Logan J, Sivaloganathan P, Collis M, Ruszkiewicz A, Brown MP. Gargett T, et al. J Immunother Cancer. 2024 May 15;12(5):e008659. doi: 10.1136/jitc-2023-008659. J Immunother Cancer. 2024. PMID: 38754916 Free PMC article. Clinical Trial.
Transition to a mesenchymal state in neuroblastoma may be characterized by a high expression of GD2 and by the acquisition of immune escape from NK cells.
Di Matteo S, Bilotta MT, Pelosi A, Haas D, Theinert T, Weber G, Schlegel PG, Berg M, Moretta L, Maggi E, Azzarone B, Vacca P, Tumino N, Caruana I. Di Matteo S, et al. Front Immunol. 2024 Apr 26;15:1382931. doi: 10.3389/fimmu.2024.1382931. eCollection 2024. Front Immunol. 2024. PMID: 38736882 Free PMC article.
Metabolic priming of GD2 TRAC-CAR T cells during manufacturing promotes memory phenotypes while enhancing persistence.
Cappabianca D, Pham D, Forsberg MH, Bugel M, Tommasi A, Lauer A, Vidugiriene J, Hrdlicka B, McHale A, Sodji QH, Skala MC, Capitini CM, Saha K. Cappabianca D, et al. Mol Ther Methods Clin Dev. 2024 Apr 10;32(2):101249. doi: 10.1016/j.omtm.2024.101249. eCollection 2024 Jun 13. Mol Ther Methods Clin Dev. 2024. PMID: 38699288 Free PMC article.
1,141 results